Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clouds Darken Over Gilead's Zydelig In Europe Amid EMA Review

This article was originally published in Scrip

Executive Summary

A fresh obstacle to Gilead Sciences Inc.'s blood cancer therapy Zydelig (idelalisib) is looming amid news the European Medicines Agency is reviewing the PI3K inhibitor's safety profile after a jump in serious adverse events, including deaths, mostly due to infections, observed in three clinical studies.

You may also be interested in...



Deal Watch: Bayer Teams With Nuvisan On Berlin-Based Small Molecule Research Group

Deal news from Bayer, Nuvisan, Inamed, BioMotiv, Bristol-Myers Squibb, Collegium, Assertio, Merck & Co., KalVista, Atreca, Coda, Attenua, Aimmune, Xencor, EyePoint, Equinox, Allergan, Nestle, Zealand, Valeritas…

Pfizer Ends Pact With GlycoMimetics After SCD Failure

GlycoMimetics’ commercial and pipeline prospects are in doubt after Pfizer terminated their 2011 sickle cell drug development deal, following a failed late-stage study.

 

Sanofi Highlights MS Asset After Solid Q4

The French drugmaker ended 2019 with a solid Q4 performance and news that its BTK inhibitor SAR442168 will start Phase III testing in progressive and elapsing multiple sclerosis. 

Topics

UsernamePublicRestriction

Register

SC064742

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel